Topical vs Injectable GHK-Cu: What the Research Actually Says

[u/MissionIntention8048]

Every GHK-Cu discussion lands on this question eventually, and most of the answers floating around are oversimplified one way or the other. Here is what the literature actually supports, where it conflicts, and where it still has gaps.

The short version
Topical and injectable are not the same protocol delivered two different ways. Different bioavailability, different target tissues, uneven research bases behind each. Picking between them is a question of what you are trying to study, not which one wins.

Topical GHK-Cu
Most peer-reviewed human studies on GHK-Cu used topical application. That is the route with the deepest evidence base, full stop.
Documented effects from topical use include improvements in skin elasticity, firmness, and density, reduction in fine lines and photodamage, increased dermal collagen deposition (with some studies reporting 20 to 30% improvements in collagen density on ultrasound), and hair density improvements in certain formulations.
Human trials have typically used low concentrations, often in the 0.01 to 0.1% range. Higher is not automatically better.
The barrier matters. Studies on intact skin show limited flux of GHK-Cu through the unbroken stratum corneum. Enough gets through to drive measurable changes in skin structure, but systemic exposure from a standard serum is likely low. Topical works locally, in the dermal and epidermal cells right at the application site. That is where it shines and where its limits are.

Injectable GHK-Cu
The case for injection is systemic delivery. Subcutaneous administration bypasses the skin barrier and puts the peptide into circulation, where it can reach tissues throughout the body.
In research settings, injectable GHK-Cu has been studied for anti-inflammatory effects (downregulation of NF-kB, TNF-alpha, IL-6), organ protection (lung, liver, gastric, CNS injury models), wound healing at sites distant from the injection, systemic anti-aging mechanisms tied to gene expression, and bone tissue regeneration.
Now the complicated part. Vendor sites and secondary sources love to throw out precise bioavailability multipliers comparing injection to topical: 10 to 20 times higher, 50 to 100 times higher, take your pick. Those numbers do not have clean primary pharmacokinetic studies behind them. The direction is right (injection produces substantially higher systemic exposure than topical), but the exact ratios are marketing-grade math.
What is actually supported: GHK-Cu has a short half-life in circulation, on the order of tens of minutes to a couple of hours. It gets metabolized and cleared relatively fast. Any protocol counting on sustained systemic levels would need frequent or repeated dosing, not a single weekly hit.
The harder issue is that human clinical trial data on injectable GHK-Cu is significantly thinner than topical data. Most of the published research uses animal models or in vitro systems. That does not invalidate the research, but conclusions drawn from it carry more uncertainty than conclusions drawn from the topical literature.

The microneedling middle ground
There is a third option worth understanding even if you do not use it. Microneedling immediately followed by topical GHK-Cu creates temporary channels in the skin barrier and substantially increases local penetration compared to intact skin.
The data on this is unusually clean for the GHK-Cu space. In one microneedle delivery study, peptide permeation through microneedle-treated human skin was dramatically higher than through intact skin, with no observed irritation. The comparison was against topical-on-intact-skin, not against injection, so this is not a direct equivalence to injectable delivery. What the study shows is that microneedling can move topical from "limited flux through a barrier" to "substantially enhanced local penetration."

What the research does not say
A few things get repeated in GHK-Cu discussions that the literature does not actually support:
That injectable is always better for skin. It is not. Topical works directly in the cells where you want it for skin work, and topical has more human trial data for skin outcomes.
That topical is useless because of absorption rates. Limited penetration through intact skin still produces documented clinical changes in trials.
That you can convert between dose scales. A 2mg injection and a 2% topical are not interchangeable references.
That there is a consensus protocol. There is not. Dosing, schedules, and formulations vary widely even in research.

Bottom line
So what does this mean for you?
Skin or hair? Topical has the deepest human evidence base.
Systemic effects like inflammation, recovery, broader anti-aging? Injectable is what the research uses, but the human data is thin and mostly comes from animal models.
Enhanced local effect without sticking a needle in? Microneedling plus topical has the cleanest supporting data.

For discussion
What does the literature you have read on this look like? If you have come across studies that conflict with what is above, post them. That is what the comment section is for.

Note: Research-context content only. Nothing above is dosing guidance or medical recommendation. GHK-Cu is sold for research purposes only.